ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,013.13
-1.71%
US Tech 100
21,038.40
-2.10%
다우존스 지수
43,428.02
-1.69%
Bitcoin
96,255.08
0.12%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Atea Pharmaceuticals Inc (AVIR) 시세

Atea Pharmaceuticals Inc

Atea Pharmaceuticals Inc (AVIR)

NASDAQ
3.09
-0.05
(-1.59%)
마감 22 2월 6:00AM
15분 지연
3.09
0.00
(0.00%)
시간외 거래: 7:16AM
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

주요 통계 및 세부정보

가격
3.09
매수가
3.00
매도가
3.30
거래량
309,138
3.05 일간 변동폭 3.19
2.30 52주 범위 4.60
market_cap
260.991M
전일 종가
3.14
개장가
3.19
최근 거래 시간
6
@
3.0001
마지막 거래 시간
재정 규모
US$ 965,729
VWAP
3.1239
평균 볼륨(3m)
433,909
발행 주식
84,463,059
배당수익률
-
주가수익률
-1.92
주당순이익(EPS)
-1.61
매출
-
순이익
-135.96M

Atea Pharmaceuticals Inc 정보

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treat... Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.ateapharma.com
본부
Wilmington, Delaware, USA
설립됨
-
Atea Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker AVIR. The last closing price for Atea Pharmaceuticals was US$3.14. Over the last year, Atea Pharmaceuticals shares have traded in a share price range of US$ 2.30 to US$ 4.60.

Atea Pharmaceuticals currently has 84,463,059 shares in issue. The market capitalisation of Atea Pharmaceuticals is US$265.21 million. Atea Pharmaceuticals has a price to earnings ratio (PE ratio) of -1.92.

AVIR 최신 뉴스

추가 뉴스

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
05 2월 2025
AVIR (-1.59%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
05 2월 2025
AVIR (-1.59%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
05 2월 2025
AVIR (-1.59%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
05 2월 2025
AVIR (-1.59%)

Form EFFECT - Notice of Effectiveness
Edgar (US Regulatory)
20 11월 2024
AVIR (-1.59%)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.05-1.59235668793.143.253.042171863.11760993CS
4-0.01-0.3225806451613.13.252.93275163.06468617CS
12-0.28-8.308605341253.373.5992.754339093.15837778CS
26-0.71-18.68421052633.84.1452.32970243.31376633CS
52-1.24-28.63741339494.334.62.32873453.54955392CS
156-2.77-47.26962457345.869.792.34650884.7507563CS
2602.2675275.6838905780.822594.17370.822582439214.80528647CS

AVIR - Frequently Asked Questions (FAQ)

What is the current Atea Pharmaceuticals share price?
The current share price of Atea Pharmaceuticals is US$ 3.09
How many Atea Pharmaceuticals shares are in issue?
Atea Pharmaceuticals has 84,463,059 shares in issue
What is the market cap of Atea Pharmaceuticals?
The market capitalisation of Atea Pharmaceuticals is USD 265.21M
What is the 1 year trading range for Atea Pharmaceuticals share price?
Atea Pharmaceuticals has traded in the range of US$ 2.30 to US$ 4.60 during the past year
What is the PE ratio of Atea Pharmaceuticals?
The price to earnings ratio of Atea Pharmaceuticals is -1.92
What is the reporting currency for Atea Pharmaceuticals?
Atea Pharmaceuticals reports financial results in USD
What is the latest annual profit for Atea Pharmaceuticals?
The latest annual profit of Atea Pharmaceuticals is USD -135.96M
What is the registered address of Atea Pharmaceuticals?
The registered address for Atea Pharmaceuticals is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Atea Pharmaceuticals website address?
The website address for Atea Pharmaceuticals is www.ateapharma.com
Which industry sector does Atea Pharmaceuticals operate in?
Atea Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
MLGOMicroAlgo Inc
US$ 6.3767
(454.50%)
531.54M
BOXLBoxlight Corporation
US$ 3.1099
(51.70%)
1.84M
GDEVGDEV Inc
US$ 20.90
(46.56%)
264.44k
IVVDInvivyd Inc
US$ 1.7501
(44.64%)
37.75M
UPCUniverse Pharmaceuticals Inc
US$ 0.2003
(40.56%)
420.21M
DOYUDouYu International Holdings Ltd
US$ 7.19
(-55.31%)
1.28M
MNDRMobile health Network Solutions
US$ 0.5048
(-46.29%)
18.61M
BLUEbluebird bio Inc
US$ 4.09
(-41.90%)
5.44M
FLDFold Holdings Inc
US$ 6.95
(-37.39%)
488.54k
GCLGCL Global Holdings Ltd
US$ 3.83
(-31.48%)
635.26k
MLGOMicroAlgo Inc
US$ 6.3767
(454.50%)
531.54M
UPCUniverse Pharmaceuticals Inc
US$ 0.2003
(40.56%)
420.21M
ADTXAditxt Inc
US$ 0.0922
(-22.39%)
278.25M
NVDANVIDIA Corporation
US$ 134.43
(-4.05%)
228.14M
HOLOMicroCloud Hologram Inc
US$ 1.565
(31.51%)
190.81M

AVIR Discussion

게시물 보기
DewDiligence DewDiligence 5 월 전
AVIR phase-3 COVID trial fails—stock rises:

https://www.globenewswire.com/news-release/2024/09/13/2945844/0/en/Atea-Pharmaceuticals-Provides-Update-on-Global-Phase-3-SUNRISE-3-Trial-Evaluating-Bemnifosbuvir-for-Treatment-of-COVID-19.html Atea Pharmaceuticals, Inc. (Nasdaq: AVIR)…today announced the outcome of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, versus placebo for the treatment of COVID-19. The trial did not meet the primary endpoint of a statistically significant reduction in all-cause hospitalization or death through Day 29 in the monotherapy cohort of 2,221 high-risk patients with mild to moderate COVID-19. This trial was a longshot insofar as Bemnifosbuvir is a repurposed HCV drug rather than something designed specifically for SARS-CoV-2. Moreover, the phase-2 trial for Bemnifosbuvir in COVID was unsuccessful, but AVIR plowed ahead anyhow.

I presume the share price is up slightly today because investors know that AVIR won’t waste more money pursuing COVID. AVIR had about $475M of net current assets as of 6/30/24.

AVIR’s CEO, Jean-Pierre Sommadossi, is continuing to pursue a treatment regimen for HCV, which is a rather extreme case of Zebra’s Law (#msg-172559198).
👍️0
Monksdream Monksdream 6 월 전
AVIR under $4
👍️0
DewDiligence DewDiligence 7 월 전
AVIR reports 2Q24 results—6/30/24 cash=$502.2M—down_from_$542M_at_3/31/24:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-second-quarter-200500091.html

CC slides:
https://ir.ateapharma.com/static-files/96ee237a-23d9-4515-8401-69794a5327e0
👍️0
DewDiligence DewDiligence 9 월 전
AVIR 1Q24 results:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-first-quarter-200500150.html

3/31/24 cash = $542M, down from $578M at 12/31/23.

Final results from the phase-3 SUNRISE COVID trial are expected in 2H24 (no change relative to the prior guidance). There are no interim analyses (#msg-174125019).
👍️0
Monksdream Monksdream 10 월 전
AVIR under $5
👍️0
DewDiligence DewDiligence 11 월 전
AVIR completes enrollment of phase-3 COVID trial—cancels interim analyses:

https://www.globenewswire.com/news-release/2024/03/27/2853010/0/en/Atea-Pharmaceuticals-Completes-Patient-Enrollment-in-Global-Phase-3-SUNRISE-3-Trial-Evaluating-Oral-Antiviral-Bemnifosbuvir-for-COVID-19-in-High-Risk-Patients.html Atea Pharmaceuticals…today announced that the company has completed enrollment of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, or placebo for the treatment of COVID-19. Over 2,200 patients were randomized into the supportive care monotherapy cohort… The primary endpoint of the trial is all-cause hospitalization or death through Day 29 post-treatment in the bemnifosbuvir supportive care monotherapy cohort of high-risk patients. The two planned interim analyses have been canceled: “Since full enrollment was achieved ahead of the two planned interim analyses for safety and futility by the Data Safety Monitoring Board (DSMB), the analyses are no longer relevant, and in agreement with the DSMB, we will proceed to the full analysis of the trial. We look forward to reporting SUNRISE-3 results in the second half of 2024…
👍️0
DewDiligence DewDiligence 12 월 전
AVIR phase-3 COVID update:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-fourth-quarter-210500983.html

The first and second interim analyses in the phase-3 COVID trial will be performed in March and in 2Q24, respectively, and the final results will be available in 2H24. 1,400 patients have been enrolled in the bemnifosbuvir monotherapy cohort (the cohort that the primary endpoint is based on).

AVIR had $578M of cash at 12/31/23, which is why they can afford to blow so much money on a longshot trial.
👍️0
DewDiligence DewDiligence 2 년 전
AVIR rejects Tang buyout offer, as expected:

https://www.globenewswire.com/news-release/2023/05/30/2678205/0/en/Atea-Pharmaceuticals%5B%E2%80%A6%5DTang-Capital-Partners-Affiliate-Concentra-Biosciences.html

The offer was for less than AVIR’s cash value.
👍️0
DewDiligence DewDiligence 2 년 전
It's not a serious offering for the reason mentioned in #msg-171974875.
👍️0
mwn mwn 2 년 전
Why is the sp going so far below the offering?
👍️0
DewDiligence DewDiligence 2 년 전
Yes.
👍️0
Paullee Paullee 2 년 전
Did you not notice that a CVR of 80% is included in the package?
👍️0
DewDiligence DewDiligence 2 년 전
In other words, AVIR could do better than $5.75/sh by simply liquidating.
👍️0
DewDiligence DewDiligence 2 년 전
AVIR acknowledges Tang buyout offer—makes_no_recommendation_to_shareholders—(yet):

https://www.globenewswire.com/news-release/2023/05/23/2674788/0/en/Atea-Pharmaceuticals-Confirms-Receipt-of-Unsolicited-Proposal-from-Tang-Capital-Partners-Affiliate-Concentra-Biosciences.html

Even thought Tang’s $5.75/sh offer is a big premium to where AVIR was trading prior to the offer, it’s less than AVIR’s cash value per share. Hence, it’s hard to see how AVIR’s BoD could accept the offer. They could make a counter-proposal, of course.
👍️0
DewDiligence DewDiligence 2 년 전
Tang Capital makes_unsolicited AVIR buyout offer@$5.75/sh +CVR—a_55%_premium_to_Friday’s_close:

https://www.sec.gov/Archives/edgar/data/1593899/000121465923007616/z519230sc13d.htm (scan to bottom)

Why does Tang want to acquire AVIR? Presumably for AVIR’s COVID drug, AT-527, such as it is. AT-527 is a polymerase inhibitor that is similar to an HCV drug BMY dropped several years ago due to toxicity. AVIR is conducting a phase-3 trial in high-risk COVID patients using a daily dose of 1100 mg (550mg BID); the trial listing is at: https://www.clinicaltrials.gov/ct2/show/NCT05629962 .
👍️0
Awl416 Awl416 2 년 전
Volume
👍️0
DewDiligence DewDiligence 2 년 전
AVIR 1Q23 CC transcript:

https://finance.yahoo.com/news/q1-2023-atea-pharmaceuticals-inc-140930636.html
👍️0
DewDiligence DewDiligence 2 년 전
AVIR 1Q23 results:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-first-quarter-200500951.html

3/31/23 cash = $621M.
👍️0
V63 V63 2 년 전
So AVIR beat its earnings, and now it might bump up a little tomorrow.
👍️0
DewDiligence DewDiligence 2 년 전
AVIR reports final data from phase-2 COVID trial:

https://www.globenewswire.com/news-release/2023/04/12/2645185/0/en/Atea-Announces-Presentation-of-Bemnifosbuvir-Data-Demonstrating-Reduced-Hospitalizations-for-COVID-19-Patients-at-2023-European-Congress-of-Clinical-Microbiology-Infectious-Disease.html
👍️0
DewDiligence DewDiligence 2 년 전
AVIR 4Q22 CC transcript:

https://finance.yahoo.com/news/atea-pharmaceuticals-inc-nasdaq-avir-022000995.html
👍️0
DewDiligence DewDiligence 2 년 전
AVIR 4Q22 results—12/31/22 cash=$647M:

https://www.globenewswire.com/news-release/2023/02/28/2617674/0/en/Atea-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html

AVIR expects the interim analysis of the SUNRISE-3 (COVID) phase-3 trial to occur in 2H23. One possible outcome of the interim analysis is increasing the number of patients to provide more statistical power for the final analysis.
👍️0
DewDiligence DewDiligence 2 년 전
AVIR JPM webcast slides:

https://ir.ateapharma.com/static-files/731c461d-37e4-4364-8a12-eb605580b0aa
👍️0
DewDiligence DewDiligence 2 년 전
AVIR 2023 newsflow:

https://finance.yahoo.com/news/atea-pharmaceuticals-highlights-strategic-priorities-120000077.html
👍️0
DewDiligence DewDiligence 2 년 전
AVIR 3Q22 results—9/30/22 cash=$665M:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-third-quarter-210500282.html

A phase-3 trial of Bemnifosbuvir (f/k/a AT-527) in 1,500 high-risk, non-hospitalized COVID patients is expected to start by the end of 2022. AVIR is defining “high-risk” as: a) age 80+; b) age 65+ with 1 or more major risk factors; or c) an immunocompromised adult of any age.

The daily dose of Bemnifosbuvir is a whopping 1100mg (550mg BID).
👍️0
DewDiligence DewDiligence 3 년 전
AVIR 2Q22 results—6/30/22_cash=$684.5M (down from $705.5M at 3/31/22):

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-second-quarter-200500782.html
👍️0
DewDiligence DewDiligence 3 년 전
AVIR 3/31/22 cash=$705.5M—burning $58.9M in 1Q22...

1Q22 PR:
https://finance.yahoo.com/news/atea-pharmaceuticals-reports-first-quarter-103000747.html

1Q22 CC slides:
https://ir.ateapharma.com/static-files/8a966559-367b-4a3b-96c0-ff21958c0562
👍️0
DewDiligence DewDiligence 3 년 전
LOL re AVIR’s attempt to be relevant:

https://www.globenewswire.com/news-release/2021/12/14/2352116/0/en/Atea-Pharmaceuticals-Introduces-New-Strategic-Clinical-Development-Program-for-AT-527-in-COVID-19.html
👍️0
Jake L Jake L 3 년 전
AVIR - Friday Rundown, Monday Expectations

👍️0
Wallst_junkie Wallst_junkie 3 년 전
Watching for a uptrend
👍️0
dealerschool2006 dealerschool2006 3 년 전
GOOD JOB!!! ya, by the time I discovered AVIR it had gone up 50% from the bottom...
👍️0
crudeoil24 crudeoil24 3 년 전
Wow! That's why you don't hold these Pharma overnight.

AVIR
👍️0
TheFinalCD TheFinalCD 3 년 전
wow went sub $11 and traded the whole float, shit it traded the whole OS 1.5x today https://finviz.com/quote.ashx?t=AVIR
👍️0
DewDiligence DewDiligence 3 년 전
Why AVIR's AT-527 program is no-go: #msg-166425975.
👍️0
XWAVXALMIMAN XWAVXALMIMAN 3 년 전
David v Goliath

Interesting article - check out RDHL

https://www.yahoo.com/entertainment/david-v-goliath-race-develop-123328764.html
👍️0
Chess Master Chess Master 3 년 전
What a drop
👍️0
ecommceo ecommceo 3 년 전
Way over sold here.
👍️0
Planopenny Planopenny 3 년 전
Out at $16, easy $$$
👍️0
Docstemcell2020 Docstemcell2020 3 년 전
Let's go Brandon! FJB :)
👍️0
DewDiligence DewDiligence 3 년 전
AVIR CC slides (largely BS, IMO):

https://ir.ateapharma.com/static-files/d72bd065-82b3-4eeb-ad3a-40c5518d66d6
👍️0
Planopenny Planopenny 3 년 전
In at $10
👍️0
rosemountbomber rosemountbomber 3 년 전
Well the shit just hit the fan. Didn’t meet primary in study. Stock dow $28
👍️0
rosemountbomber rosemountbomber 3 년 전
Thanks DD
👍️0
DewDiligence DewDiligence 3 년 전
The primary endpoint in MRK’s molnupiravir trial was the proportion of patients, relative to placebo, who died or needed hospitalization within 28 days:

https://clinicaltrials.gov/ct2/show/NCT04575597
👍️0
rosemountbomber rosemountbomber 3 년 전
So I have to confess to my ignorance when it comes to anti-viral clinical trials. It appears that the primary outcome studied in the AT-527 phase 3 trial is evaluated using a Covid 19 Symptom Diary. It does not sound like it is something very precise when asking a patient to score themselves on these 12 questions (which I have not exactly found yet).

But my question is, did the Merck drug molnupiravir get tested using this same method (symptom diary)? It must have been more than that at least as they also measure deaths, etc. - although that may have been secondary outcomes.
👍️0
Whalatane Whalatane 3 년 전
AVIR presentation tomorrow Oct 5th

https://newsfilter.io/articles/atea-pharmaceuticals-to-present-at-guggenheim-2nd-annual-vaccines--infectious-day-conference-42a958b2016103f267b2f6525ac4ac0c

Kiwi
👍️0
crudeoil24 crudeoil24 3 년 전
You bet! > AVIR up 45% @ 50.05
👍️0
Whalatane Whalatane 3 년 전
Thx for the updates

Kiwi
👍️0
crudeoil24 crudeoil24 3 년 전
AVIR up 45% @ 50.05 > premarket.
👍️0
crudeoil24 crudeoil24 3 년 전
AVIR > 53M share trading float.
👍️0

최근 히스토리

NASDAQ
AVIR
Atea Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지